Oncology Thesis Topics

Oncology thesis topics represent one of the most scientifically expansive and clinically consequential areas within health thesis topics, drawing graduate students at American universities into a discipline that addresses the full spectrum of cancer biology, prevention, diagnosis, treatment, survivorship, and the health systems that deliver cancer care to millions of Americans annually. Oncology encompasses molecular cancer biology, cancer epidemiology, surgical oncology, radiation oncology, medical oncology, immunotherapy, precision medicine, palliative care, and the growing fields of cancer health disparities and cancer outcomes research. As cancer remains the second leading cause of death in the United States and as the pace of therapeutic innovation — from immune checkpoint inhibitors to CAR-T cell therapies to targeted molecular agents — accelerates dramatically, the research questions animating oncology thesis topics have never been more scientifically rich or clinically transformative.

Oncology Thesis Topics and Research Areas

The discipline of oncology research spans molecular biology laboratories investigating the genetic drivers of cancer initiation and progression, epidemiological studies characterizing cancer risk across American populations, clinical trials evaluating novel therapeutic agents, and health services research examining how cancer care quality and outcomes vary across American health systems. Graduate students pursuing oncology thesis topics engage with genomic sequencing, immuno-oncology, clinical trial methodology, cancer registry analysis, patient-reported outcome measurement, and implementation science frameworks for improving cancer care delivery across the diverse landscape of American oncology practice. The 200 oncology thesis topics organized below into 10 thematic categories are designed to be research-ready at American cancer centers, oncology fellowship research programs, cancer epidemiology doctoral programs, and the National Cancer Institute-designated comprehensive cancer centers that anchor American cancer research.

1. Cancer Biology and Molecular Oncology

Cancer biology and molecular oncology address the fundamental mechanisms through which normal cells transform into malignant ones — encompassing oncogene activation, tumor suppressor inactivation, genomic instability, epigenetic reprogramming, metabolic rewiring, and the tumor microenvironment interactions that enable cancer progression and metastasis. This category of oncology thesis topics provides the scientific foundation for all therapeutic innovation in oncology, with discoveries about cancer molecular mechanisms directly informing the development of targeted therapies and immunotherapies that have transformed outcomes for American cancer patients. Graduate students at American cancer research universities contribute to understanding the biological vulnerabilities of cancer cells that can be exploited therapeutically.

1. Investigating the synthetic lethal interaction between PARP inhibition and homologous recombination repair deficiency in BRCA1 and BRCA2-mutant cancer cell lines and patient-derived organoid models
2. Analyzing the tumor microenvironment cellular composition changes — including T cell exhaustion, myeloid-derived suppressor cell infiltration, and cancer-associated fibroblast activation — that mediate resistance to checkpoint inhibitor immunotherapy
3. Developing a single-cell RNA sequencing approach for characterizing intratumoral heterogeneity in American patient-derived glioblastoma specimens and identifying subclonal populations associated with treatment resistance
4. Characterizing the epigenetic reprogramming mechanisms through which cancer cells acquire mesenchymal features during epithelial-to-mesenchymal transition that promote metastatic dissemination
5. Investigating the liquid biopsy circulating tumor DNA dynamics as a pharmacodynamic biomarker for monitoring treatment response and detecting resistance emergence in American lung cancer patients receiving targeted therapy
6. Analyzing the tumor metabolic reprogramming patterns — including glutamine addiction and lipid synthesis upregulation — that represent therapeutic vulnerabilities in KRAS-mutant pancreatic ductal adenocarcinoma
7. Developing a patient-derived xenograft platform from American cancer patients with rare solid tumors for preclinical drug sensitivity testing and biomarker discovery
8. Characterizing the DNA damage response pathway alterations that determine platinum chemotherapy sensitivity and resistance in American ovarian cancer cell lines and patient tumor samples
9. Investigating the cancer stem cell population dynamics and their contribution to tumor recurrence following standard chemotherapy in American patient-derived colorectal cancer organoid models
10. Analyzing the oncogenic signaling network rewiring that mediates acquired resistance to EGFR-targeted therapy in American non-small cell lung cancer patients using serial tumor biopsy and circulating tumor DNA
11. Developing a CRISPR-based functional genomics screen for identifying synthetic lethal vulnerabilities in microsatellite stable colorectal cancer that could inform novel therapeutic combinations
12. Characterizing the tumor immune evasion mechanisms — including MHC class I downregulation and immunosuppressive cytokine production — in American pancreatic cancer specimens using multiplex immunofluorescence
13. Investigating the role of the tumor microbiome in modulating chemotherapy drug metabolism and immune response in American colorectal cancer patients using paired tumor and adjacent tissue microbiome profiling
14. Analyzing the telomere maintenance mechanism — including alternative lengthening of telomeres — patterns and their therapeutic targeting potential in American pediatric high-grade glioma cell lines
15. Developing a spatial transcriptomics approach for mapping tumor-immune interaction zones and their relationship to checkpoint inhibitor response in American melanoma patient tumor specimens
16. Characterizing the oncogenic driver mutation landscape of American cancer patients enrolled in NCI-MATCH precision oncology trial and evaluating targeted therapy response by molecular subtype
17. Investigating the ferroptosis susceptibility determinants in cancer cells and the therapeutic potential of ferroptosis-inducing agents for KRAS-mutant American lung adenocarcinoma treatment
18. Analyzing the non-coding RNA regulatory network disruptions contributing to chemotherapy resistance in American triple-negative breast cancer cell lines and patient-derived models
19. Developing a patient-derived organoid drug sensitivity testing platform for American gastric cancer patients and evaluating its concordance with clinical treatment response outcomes
20. Characterizing the immune checkpoint molecule expression patterns and tumor mutational burden associations in American rare cancer histologies underrepresented in existing immunotherapy trials

2. Cancer Epidemiology and Prevention

Cancer epidemiology examines the distribution and determinants of cancer across American populations — identifying modifiable risk factors, characterizing disparate cancer burdens, and evaluating the preventive interventions that can reduce cancer incidence and mortality at the population level. This category of oncology thesis topics draws on prospective cohort studies, case-control designs, cancer registry analysis, and molecular epidemiology to understand why some Americans develop cancer and others do not, and how preventive strategies from HPV vaccination to colorectal cancer screening can reduce the American cancer burden. Graduate students contribute to evidence that directly informs American cancer prevention guidelines and public health policy.

21. Investigating the relationship between ultra-processed food consumption and colorectal cancer incidence in American adults using prospective dietary assessment linked to cancer registry outcomes
22. Analyzing the HPV vaccination coverage rates and cervical cancer incidence trends in American adolescents and young adults following introduction of the national vaccination program using SEER registry data
23. Developing a lung cancer screening eligibility expansion model for American adults with lower smoking history than current USPSTF criteria and evaluating projected mortality reduction and overdiagnosis trade-offs
24. Characterizing the occupational carcinogen exposure patterns and cancer incidence in American agricultural workers using linked occupational exposure and cancer registry data
25. Investigating the relationship between neighborhood socioeconomic deprivation and stage at cancer diagnosis across common cancer types in American adults using SEER-Medicare linked data
26. Analyzing the alcohol consumption patterns and cancer risk associations across cancer sites in American adults using dose-response methodology and population-attributable fraction estimation
27. Developing a population-based cancer risk prediction model incorporating genetic, lifestyle, and environmental factors for American adults and evaluating its performance for guiding screening recommendations
28. Characterizing the cancer incidence disparities between American racial and ethnic groups across cancer sites and evaluating the relative contributions of risk factor prevalence versus screening access
29. Investigating the obesity and adiposity measures — including body mass index, waist circumference, and visceral fat — and their differential associations with cancer risk across sites in American cohort studies
30. Analyzing the radon gas residential exposure patterns and lung cancer risk in American non-smokers using county-level radon measurement and lung cancer registry data linkage
31. Developing a chemoprevention program evaluation framework for American adults at elevated colorectal cancer risk using aspirin and other chemopreventive agents based on risk-stratified benefit-harm analysis
32. Characterizing the age-period-cohort effects in thyroid cancer incidence trends in American adults and evaluating the relative contributions of overdiagnosis versus true incidence increase
33. Investigating the physical activity dose-response relationships and cancer risk reduction across multiple cancer sites in American adults using accelerometry-measured physical activity in prospective cohort studies
34. Analyzing the tobacco product use patterns — including e-cigarettes, smokeless tobacco, and combustible cigarettes — and their cancer risk implications for American adolescents and young adults
35. Developing a hereditary cancer syndrome identification program for American primary care settings and evaluating its effectiveness in increasing appropriate genetic testing referral rates
36. Characterizing the geographic clustering patterns of rare cancer histologies in American communities and evaluating the relationship between cluster locations and environmental exposure patterns
37. Investigating the menopausal hormone therapy formulation and duration associations with breast cancer risk in American postmenopausal women using pharmacy claims and cancer registry linkage
38. Analyzing the microbiome compositional patterns and their prospective association with colorectal cancer incidence in American adults using baseline stool microbiome samples from prospective cohort studies
39. Developing a skin cancer prevention program for American outdoor workers with high ultraviolet radiation exposure using sunscreen provision, protective clothing, and behavioral counseling components
40. Characterizing the cancer incidence and mortality patterns in American veterans compared to the general population across cancer types and evaluating the role of military service-related exposures

3. Cancer Screening and Early Detection

Cancer screening represents one of the most impactful and also most complex areas of oncology research — with evidence-based screening programs for breast, colorectal, cervical, and lung cancer having the potential to dramatically reduce American cancer mortality, while simultaneously raising important questions about overdiagnosis, false positives, equity of access, and the implementation challenges of achieving recommended screening rates across diverse American populations. This category of oncology thesis topics addresses screening program effectiveness, equity of implementation, novel early detection technologies, and the shared decision-making frameworks needed to help American patients make informed screening choices.

41. Investigating the real-world colorectal cancer screening completion rates and cancer detection yields of colonoscopy versus fecal immunochemical test versus multi-target stool DNA screening in American community practice settings
42. Analyzing the racial and socioeconomic disparities in mammography screening adherence and interval cancer rates across American breast imaging practices using population-based registry data
43. Developing a multi-cancer early detection test clinical validation study using cell-free DNA methylation analysis in American adults and evaluating its sensitivity and specificity across cancer types and stages
44. Characterizing the lung cancer screening program implementation barriers and facilitators in American safety-net hospitals and federally qualified health centers serving high-risk low-income populations
45. Investigating the prostate cancer screening shared decision-making quality and PSA testing patterns following USPSTF guideline changes in American primary care settings using electronic health record data
46. Analyzing the colonoscopy quality indicators — including adenoma detection rate and cecal intubation rate — and their relationship to interval colorectal cancer incidence in American gastroenterology practices
47. Developing a patient navigation program for reducing time from abnormal cancer screening result to diagnostic resolution in American rural communities and evaluating its equity impact
48. Characterizing the false positive mammography recall rate variation across American breast imaging centers and evaluating the patient anxiety, cost, and downstream utilization consequences
49. Investigating the primary HPV testing performance compared to cytology-based cervical cancer screening in American women aged twenty-five to sixty-five using a pragmatic randomized trial design
50. Analyzing the lung cancer screening eligibility and uptake patterns in American primary care settings and evaluating the clinical and demographic factors most strongly associated with screening non-initiation
51. Developing a risk-stratified breast cancer screening protocol for American women based on validated lifetime risk models and evaluating its performance relative to age-based universal screening
52. Characterizing the colorectal cancer screening disparities between American adults with and without disabilities and evaluating accessible screening program design modifications
53. Investigating the multi-cancer early detection test performance characteristics and clinical utility for supplementing current cancer-specific screening programs in American adults over fifty
54. Analyzing the hepatocellular carcinoma surveillance program adherence and early-stage detection rates in American adults with cirrhosis across different healthcare settings and surveillance modalities
55. Developing a community health worker-delivered cancer screening promotion program for American communities with persistently low colorectal and breast cancer screening rates and evaluating its reach and effectiveness

4. Cancer Treatment — Medical Oncology

Medical oncology encompasses the systemic treatment of cancer — including cytotoxic chemotherapy, targeted molecular therapy, immunotherapy, and endocrine therapy — and represents the area of oncology experiencing the most rapid therapeutic innovation. This category of oncology thesis topics addresses the clinical effectiveness of established and novel systemic therapies, pharmacological optimization of cancer treatment, predictive biomarker development, resistance mechanisms, and the real-world implementation of evidence-based cancer treatment guidelines across American oncology practices.

56. Investigating the real-world effectiveness and safety of pembrolizumab monotherapy for advanced non-small cell lung cancer with high PD-L1 expression in American community oncology settings
57. Analyzing the KRAS G12C inhibitor sotorasib and adagrasib clinical outcomes and resistance mechanism patterns in American patients with previously treated KRAS G12C-mutant non-small cell lung cancer
58. Developing a pharmacokinetic-pharmacodynamic model for optimizing PARP inhibitor dosing in American ovarian cancer patients with BRCA mutations to maximize efficacy while managing hematological toxicity
59. Characterizing the immune-related adverse event management practices and outcome patterns for American patients receiving combination checkpoint inhibitor therapy with PD-1 and CTLA-4 blockade
60. Investigating the neoadjuvant immunotherapy effectiveness for increasing pathological complete response rates in American patients with resectable non-small cell lung cancer using a randomized trial design
61. Analyzing the antibody-drug conjugate trastuzumab deruxtecan clinical outcomes across HER2 expression levels in American patients with HER2-low breast cancer using real-world data
62. Developing a treatment sequencing decision framework for American patients with metastatic hormone receptor-positive HER2-negative breast cancer following CDK4/6 inhibitor progression
63. Characterizing the tumor mutational burden threshold and mismatch repair deficiency status associations with checkpoint inhibitor response across cancer types in American pan-tumor cohort studies
64. Investigating the bispecific antibody mosunetuzumab and epcoritamab clinical outcomes and toxicity management patterns in American patients with relapsed or refractory follicular lymphoma
65. Analyzing the real-world chimeric antigen receptor T cell therapy outcomes including response rates, toxicity, and hospital resource utilization across American academic and community cancer centers
66. Developing a clinical decision support tool for selecting between available targeted therapy options in American patients with newly diagnosed metastatic non-small cell lung cancer based on molecular profiling
67. Characterizing the liquid biopsy circulating tumor DNA clearance patterns following chemotherapy initiation and their relationship to treatment response and survival in American colorectal cancer patients
68. Investigating the long-term survivors of metastatic melanoma following checkpoint inhibitor therapy in American oncology programs and characterizing the clinical and biological features associated with durable remission
69. Analyzing the cancer cachexia prevalence and its treatment with anamorelin in American patients with non-small cell lung cancer and weight loss using a randomized controlled trial design
70. Developing a pharmacist-led oral chemotherapy adherence program for American cancer patients and evaluating its impact on treatment persistence and clinical outcome quality

5. Radiation Oncology

Radiation oncology uses ionizing radiation to treat cancer — with techniques ranging from conventional external beam radiation to stereotactic body radiation therapy, proton beam therapy, and brachytherapy — and continues to evolve rapidly through advances in image guidance, treatment planning, and radiation biology that enable more precise tumor targeting with reduced normal tissue toxicity. This category of oncology thesis topics addresses radiation treatment efficacy, normal tissue toxicity management, radiation biology, and the comparative effectiveness of different radiation modalities for common American cancer diagnoses.

71. Investigating the stereotactic body radiation therapy versus conventional fractionated radiation therapy comparative effectiveness for early-stage non-small cell lung cancer in American medically inoperable patients
72. Analyzing the proton beam therapy versus intensity-modulated radiation therapy comparative toxicity and tumor control outcomes for American patients with head and neck cancer using propensity-matched registry data
73. Developing a deep learning automated treatment planning system for prostate cancer radiation therapy and evaluating its plan quality compared to dosimetrist-generated plans in American radiation oncology centers
74. Characterizing the radiation-induced lymphopenia patterns and their prognostic significance for immunotherapy outcomes in American patients with non-small cell lung cancer receiving concurrent chemoradiation
75. Investigating the stereotactic radiosurgery versus whole brain radiation therapy comparative cognitive outcome and intracranial control in American patients with one to ten brain metastases
76. Analyzing the adaptive radiation therapy protocol effectiveness for reducing treatment toxicity in American patients with head and neck cancer using weekly MRI-guided replanning
77. Developing a patient-reported outcome monitoring program for American radiation oncology patients and evaluating its effectiveness in early detection and management of acute radiation toxicity
78. Characterizing the radiation dose fractionation optimization for stereotactic body radiation therapy of oligometastatic disease in American cancer patients receiving concurrent systemic therapy
79. Investigating the magnetic resonance-guided radiation therapy versus CT-guided radiation therapy comparative accuracy and toxicity for American patients with pancreatic cancer using online adaptive planning
80. Analyzing the brachytherapy versus external beam radiation boost comparative outcomes for American patients with high-risk prostate cancer using population-based registry data with long-term follow-up

6. Surgical Oncology

Surgical oncology addresses the role of surgery in cancer diagnosis, staging, and treatment — from minimally invasive biopsy procedures to complex multi-organ resections — and continues to evolve through laparoscopic and robotic approaches, neoadjuvant therapy integration, and the growing evidence for organ preservation strategies that maintain quality of life without compromising oncological outcomes. This category of oncology thesis topics addresses surgical technique outcomes, perioperative management, oncological margins, lymph node assessment, and the health services research questions surrounding surgical quality and access for American cancer patients.

81. Investigating the robotic versus open pancreaticoduodenectomy comparative oncological outcomes and perioperative complication rates in American hepatopancreatobiliary surgery centers
82. Analyzing the sentinel lymph node biopsy omission safety in American women with clinically node-negative early-stage breast cancer following neoadjuvant chemotherapy using a prospective cohort design
83. Developing a surgical quality improvement program for American colorectal cancer centers based on complete mesocolic excision technique adoption and evaluating its impact on local recurrence rates
84. Characterizing the minimally invasive esophagectomy outcomes compared to open esophagectomy for American patients with esophageal cancer using Society of Thoracic Surgeons database analysis
85. Investigating the nipple-sparing mastectomy oncological safety and patient-reported outcome advantages in American women with BRCA mutations undergoing risk-reducing bilateral mastectomy
86. Analyzing the cytoreductive surgery and hyperthermic intraperitoneal chemotherapy outcomes for American patients with colorectal peritoneal metastases across centers with different procedure volumes
87. Developing a perioperative immunonutrition optimization program for American patients undergoing major cancer surgery and evaluating its impact on complications and recovery
88. Characterizing the surgical margin status patterns and re-excision rates for American women undergoing breast-conserving surgery across different surgical volume and practice setting categories
89. Investigating the watchful waiting versus immediate surgery for American patients with low-risk papillary thyroid microcarcinoma and evaluating anxiety, quality of life, and oncological outcomes
90. Analyzing the lymphedema prevention effectiveness of axillary reverse mapping during sentinel lymph node biopsy in American breast cancer patients using prospective lymphoscintigraphy methodology

7. Palliative Care and Cancer Survivorship

Palliative care and survivorship research addresses the quality of life, symptom burden, psychological wellbeing, and long-term health consequences of cancer and its treatment — encompassing the growing population of more than eighteen million American cancer survivors and the integration of palliative care into oncology practice from diagnosis through the end of life. This category of oncology thesis topics examines symptom management, advance care planning, survivorship care planning, the late effects of cancer treatment, and the psychological dimensions of living with and beyond cancer in American populations.

91. Investigating the early palliative care integration effectiveness on quality of life, symptom burden, and healthcare utilization in American adults with newly diagnosed advanced lung cancer using a randomized trial design
92. Analyzing the serious illness conversation program implementation and its impact on advance directive completion rates and goal-concordant care in American oncology outpatient practices
93. Developing a survivorship care plan implementation program for American breast cancer survivors completing active treatment and evaluating its effectiveness in improving surveillance adherence and health behavior
94. Characterizing the chronic pain management practices and opioid prescribing patterns in American cancer survivorship clinics and their relationship to functional outcomes and quality of life
95. Investigating the cancer-related fatigue prevalence, trajectory, and evidence-based intervention effectiveness in American long-term cancer survivors more than five years from diagnosis
96. Analyzing the cardiovascular late effects prevalence and monitoring practices in American childhood cancer survivors treated with anthracyclines and cardiac radiation using the Childhood Cancer Survivor Study data
97. Developing a cognitive rehabilitation program for American cancer survivors with chemotherapy-related cognitive impairment and evaluating its effectiveness on neuropsychological performance and quality of life
98. Characterizing the financial toxicity burden and its health behavior and quality of life consequences for American cancer patients with high out-of-pocket cancer treatment costs
99. Investigating the advance care planning documentation quality and treatment concordance at end of life in American adults with advanced cancer across different healthcare settings
100. Analyzing the sexual health outcomes and intervention needs of American cancer survivors across cancer types and treatment modalities using patient-reported outcome methodology

8. Cancer Health Disparities and Equity

Cancer health disparities — the systematic differences in cancer incidence, stage at diagnosis, treatment receipt, and survival that fall along racial, socioeconomic, geographic, and other social lines — represent one of the most important and persistent challenges in American oncology. This category of oncology thesis topics examines the mechanisms driving cancer disparities, evaluates the effectiveness of disparity-reduction interventions, and investigates how American cancer care systems can be redesigned to provide equitable, high-quality care for all cancer patients regardless of their social background. Graduate students contribute to evidence that directly informs American cancer care equity policy and practice.

101. Investigating the racial disparities in stage at colorectal cancer diagnosis and their relationship to screening access, primary care utilization, and patient navigation program availability across American states
102. Analyzing the socioeconomic determinants of cancer treatment abandonment and incomplete therapy in American adults with breast, colorectal, and lung cancer using population-based registry and claims data
103. Developing a patient navigation program for reducing racial disparities in breast cancer treatment initiation time in American safety-net hospitals and evaluating its equity impact
104. Characterizing the rural-urban disparities in cancer survival for the most common cancer types in American adults and evaluating the relative contributions of late-stage diagnosis and treatment quality differences
105. Investigating the insurance coverage type and cancer treatment receipt disparities in American adults before and after Affordable Care Act Medicaid expansion using difference-in-differences methodology
106. Analyzing the clinical trial enrollment disparities for American Black, Hispanic, and low-income cancer patients and evaluating the eligibility criterion and logistical barrier contributions to underrepresentation
107. Developing a community-based participatory research program for co-designing cancer screening promotion interventions with American communities experiencing persistently low screening rates
108. Characterizing the cancer information access patterns and health literacy barriers affecting American cancer patients from limited English proficiency backgrounds in their treatment decision-making
109. Investigating the relationship between residential exposure to environmental carcinogens and cancer incidence disparities in American environmental justice communities using geospatial and registry linkage methodology
110. Analyzing the palliative care and hospice utilization disparities between American racial and ethnic groups in the last six months of life using Medicare claims and cancer registry data

9. Precision Oncology and Biomarker Development

Precision oncology — matching cancer treatments to the specific molecular characteristics of individual tumors and patients — has transformed cancer care through the identification of actionable genomic alterations, predictive biomarkers for immunotherapy response, and pharmacogenomic predictors of treatment toxicity. This category of oncology thesis topics addresses the development and clinical validation of oncology biomarkers, the design of biomarker-selected clinical trials, the implementation of tumor molecular profiling in American oncology practice, and the equity challenges of ensuring that precision oncology benefits reach all American cancer patients.

111. Investigating the comprehensive genomic profiling clinical utility for identifying actionable alterations and guiding treatment selection in American patients with advanced solid tumors beyond standard-of-care molecular testing
112. Analyzing the tumor mutational burden assay harmonization challenges and clinical interpretation consistency across American commercial laboratory platforms using reference standard samples
113. Developing a minimal residual disease monitoring program using circulating tumor DNA for American patients with early-stage colorectal cancer following curative resection and evaluating its recurrence prediction accuracy
114. Characterizing the homologous recombination deficiency biomarker performance for predicting PARP inhibitor benefit in American patients with ovarian cancer beyond BRCA mutation status
115. Investigating the NCI-MATCH precision oncology trial treatment arm outcome patterns and the relationship between specific genomic alterations and targeted therapy response rates in American cancer patients
116. Analyzing the tissue of origin accuracy of multi-cancer early detection tests in American patients with cancer of unknown primary using cell-free DNA methylation analysis
117. Developing a tumor mutational burden and microsatellite instability testing protocol optimization for American pathology laboratories to improve checkpoint inhibitor patient selection accuracy
118. Characterizing the liquid biopsy comprehensive genomic profiling concordance with tissue biopsy in American patients with advanced cancer across different tumor types and circulating tumor DNA shedding levels
119. Investigating the pharmacogenomic variant prevalence and clinical actionability for cancer drug metabolism genes in American cancer patients from diverse racial and ethnic backgrounds
120. Analyzing the precision oncology clinical trial enrollment patterns and biomarker-selected therapy access equity across American National Cancer Institute-designated cancer center versus community oncology settings

10. Hematological Malignancies

Hematological malignancies — including leukemias, lymphomas, multiple myeloma, and myelodysplastic syndromes — have experienced some of the most dramatic treatment advances in oncology over the past decade, with CAR-T cell therapies, bispecific antibodies, targeted kinase inhibitors, and novel immunomodulatory agents transforming outcomes for American patients with blood cancers. This category of oncology thesis topics addresses the biology, treatment, and outcomes of hematological malignancies across the spectrum from indolent to highly aggressive disease.

121. Investigating the CAR-T cell therapy real-world outcomes and toxicity management patterns for American patients with relapsed or refractory large B-cell lymphoma outside of clinical trial settings
122. Analyzing the venetoclax and azacitidine combination therapy clinical outcomes in American older adults with newly diagnosed acute myeloid leukemia ineligible for intensive chemotherapy
123. Developing a minimal residual disease-guided treatment intensification and de-escalation protocol for American adults with acute lymphoblastic leukemia receiving frontline chemotherapy
124. Characterizing the ibrutinib versus acalabrutinib versus zanubrutinib comparative cardiovascular toxicity and clinical efficacy profiles in American patients with chronic lymphocytic leukemia
125. Investigating the bispecific antibody teclistamab and elranatamab clinical outcomes and cytokine release syndrome management patterns in American patients with heavily pretreated multiple myeloma
126. Analyzing the allogeneic stem cell transplantation outcomes and graft-versus-host disease management patterns in American adult patients with high-risk myelodysplastic syndrome across transplant center volume categories
127. Developing a genomic risk stratification-guided treatment selection framework for American patients with newly diagnosed diffuse large B-cell lymphoma using cell-of-origin and double-hit lymphoma classification
128. Characterizing the racial disparities in multiple myeloma incidence, treatment receipt, and survival in American adults and evaluating the biological and health system factors contributing to differential outcomes
129. Investigating the chronic myeloid leukemia treatment-free remission durability and molecular recurrence patterns in American patients discontinuing tyrosine kinase inhibitor therapy after sustained deep molecular response
130. Analyzing the Hodgkin lymphoma treatment de-escalation strategy outcomes in American adolescent and young adult patients using PET-adapted chemotherapy reduction approaches

11. Pediatric Oncology

Pediatric oncology addresses cancer in children and adolescents — including leukemias, brain tumors, lymphomas, sarcomas, neuroblastoma, and Wilms tumor — with American childhood cancer survival rates having improved dramatically over recent decades through cooperative group clinical trials, yet with important research questions remaining about reducing treatment toxicity, managing relapsed disease, and supporting long-term survivor health. This category of oncology thesis topics examines pediatric cancer biology, treatment optimization, late effects, and the psychosocial dimensions of childhood cancer for patients, families, and survivors.

131. Investigating the immunotherapy integration into frontline therapy for American children with newly diagnosed high-risk neuroblastoma and evaluating its impact on event-free survival and toxicity
132. Analyzing the proton beam therapy toxicity advantages for American children with brain tumors and evaluating neurocognitive outcome improvements compared to photon radiation therapy
133. Developing a genomic-guided treatment selection protocol for American children with relapsed or refractory solid tumors enrolled in pediatric precision oncology programs
134. Characterizing the late cardiac effects and cardioprotective intervention outcomes in American childhood cancer survivors treated with anthracyclines using the Childhood Cancer Survivor Study cohort
135. Investigating the CAR-T cell therapy outcomes for American children with relapsed or refractory B-cell acute lymphoblastic leukemia and evaluating the predictors of durable remission
136. Analyzing the neurocognitive late effects and academic outcomes in American childhood brain tumor survivors using longitudinal cognitive assessment and educational record linkage
137. Developing a family-centered psychosocial support program for American parents of children with newly diagnosed cancer and evaluating its impact on parental anxiety, depression, and family functioning
138. Characterizing the health-related quality of life trajectories in American adolescent and young adult cancer survivors from diagnosis through long-term survivorship using validated patient-reported outcomes
139. Investigating the fertility preservation counseling and procedure utilization patterns in American adolescent cancer patients and evaluating the barriers to timely fertility preservation referral
140. Analyzing the transition from pediatric to adult cancer survivorship care quality and healthcare engagement patterns for American young adults treated for childhood cancer

12. Emerging Oncology Frontiers

Emerging oncology frontiers encompass the most innovative and potentially transformative research directions in cancer medicine — including personalized cancer vaccines, oncolytic virotherapy, cancer metabolomics, the tumor-immune microenvironment, epigenetic cancer therapy, and the convergence of artificial intelligence with oncology — creating a forward-looking category of oncology thesis topics that engages graduate students with the discoveries that will define cancer care for the next generation of American patients.

141. Investigating the personalized mRNA neoantigen cancer vaccine immunogenicity and clinical efficacy in American melanoma and non-small cell lung cancer patients as adjuvant therapy following resection
142. Analyzing the oncolytic herpes simplex virus talimogene laherparepvec abscopal effect induction and systemic immune activation patterns in American melanoma patients with uninjected metastatic lesions
143. Developing a cancer metabolism-targeting strategy combining glutaminase inhibition with checkpoint immunotherapy and evaluating its efficacy in American triple-negative breast cancer xenograft models
144. Characterizing the tumor microenvironment immune cell spatial organization patterns and their relationship to checkpoint inhibitor response in American gastric cancer patients using spatial transcriptomics
145. Investigating the epigenetic therapy combination strategies — including HDAC inhibitor and DNA methyltransferase inhibitor combinations — for restoring immune recognition in American microsatellite stable colorectal cancer
146. Analyzing the artificial intelligence-assisted histopathological image analysis performance for predicting molecular subtypes and clinical outcomes in American cancer pathology archives
147. Developing a cancer interception strategy targeting premalignant lesions in American adults at high risk for lung cancer using epigenetic biomarker-guided intervention selection
148. Characterizing the bispecific CAR-T cell construct design parameters for simultaneously targeting two tumor antigens to reduce antigen escape and improve response durability in American hematological malignancy patients
149. Investigating the senolytic therapy potential for eliminating therapy-induced senescent cancer cells that contribute to treatment resistance and recurrence in American breast cancer models
150. Analyzing the cancer-associated microbiome composition patterns and their functional relationship to checkpoint inhibitor immunotherapy response in American melanoma and lung cancer patients

13. Cancer Care Delivery and Health Services Research

Cancer care delivery and health services research examines how cancer care is organized, financed, and delivered across American health systems — addressing quality of care measurement, value-based cancer care models, cancer care team composition, survivorship care delivery, and the policy frameworks that shape how American cancer patients access and experience care. Graduate students contribute to understanding how system-level factors influence cancer outcomes and how American oncology practices can be designed to deliver higher-quality, more equitable, and more patient-centered cancer care.

151. Investigating the National Cancer Institute cancer center designation impact on cancer treatment quality and survival outcomes for American patients with common cancers across urban and rural communities
152. Analyzing the oncologist workforce supply and demand projections and their geographic distribution implications for American cancer care access over the next two decades
153. Developing a value-based cancer care payment model for American oncology practices and evaluating its impact on chemotherapy prescribing appropriateness and total cancer care costs
154. Characterizing the multidisciplinary tumor board utilization patterns and their relationship to treatment plan concordance with national guidelines across American cancer center and community oncology settings
155. Investigating the financial toxicity screening and intervention program effectiveness in American oncology practices for reducing treatment abandonment and out-of-pocket burden in commercially insured patients
156. Analyzing the clinical trial infrastructure and enrollment capacity disparities between American National Cancer Institute-designated cancer centers and community oncology practices
157. Developing a distress thermometer and problem list-based psychosocial screening and referral program for American oncology outpatient practices and evaluating its implementation and patient outcome effectiveness
158. Characterizing the home-based cancer treatment model safety and patient experience outcomes for American adults receiving oral and subcutaneous cancer therapies outside of infusion center settings
159. Investigating the teleoncology program effectiveness for providing specialist cancer care consultation to American rural cancer patients and evaluating its impact on treatment guideline concordance
160. Analyzing the hospice utilization patterns and timing in American cancer patients and evaluating the clinical and demographic factors most strongly associated with late hospice enrollment or non-enrollment

14. Immunotherapy and Cancer Immunology

Cancer immunotherapy has been one of the most transformative developments in oncology over the past decade — with immune checkpoint inhibitors, CAR-T cell therapies, cancer vaccines, and tumor-infiltrating lymphocyte therapies producing durable responses and even cures in cancers that were previously uniformly fatal. This category of oncology thesis topics addresses the fundamental immunology of cancer-immune interactions, the clinical effectiveness and toxicity of immunotherapy across cancer types, the biomarkers that predict immunotherapy response, and the next generation of immunotherapy strategies being developed at American cancer research programs.

161. Investigating the combination nivolumab plus ipilimumab versus nivolumab monotherapy long-term survival outcomes in American patients with advanced melanoma using ten-year follow-up data from CheckMate trials
162. Analyzing the PD-L1 expression assay concordance across different antibody clones and scoring platforms and its implications for checkpoint inhibitor patient selection in American pathology laboratory settings
163. Developing a tumor-infiltrating lymphocyte therapy manufacturing and clinical protocol for American patients with metastatic melanoma and evaluating its response rate and durability compared to checkpoint inhibitors
164. Characterizing the immune-related adverse event risk factors and severity predictors across organ systems in American patients receiving checkpoint inhibitor monotherapy and combination immunotherapy
165. Investigating the innate immune pathway activation strategies — including STING agonists and TLR agonists — for enhancing checkpoint inhibitor efficacy in American patients with immune-excluded solid tumors
166. Analyzing the clonal neoantigen burden and T cell receptor repertoire diversity associations with checkpoint inhibitor response durability in American patients with advanced non-small cell lung cancer
167. Developing a bispecific T cell engager therapy protocol for American patients with platinum-resistant ovarian cancer and evaluating its efficacy and cytokine release syndrome management
168. Characterizing the regulatory T cell depletion strategies for enhancing antitumor immunity without inducing autoimmunity in American preclinical cancer models and early phase clinical studies
169. Investigating the adaptive resistance mechanisms to checkpoint inhibitor therapy — including interferon-gamma pathway loss and alternative immune checkpoint upregulation — in American patients with acquired resistance
170. Analyzing the cancer vaccine clinical trial design considerations for evaluating personalized neoantigen vaccines in American patients across different cancer types and disease settings

15. Gastrointestinal Oncology

Gastrointestinal cancers — including colorectal, gastric, pancreatic, hepatocellular, and esophageal cancers — collectively represent one of the largest cancer burdens in the United States, with colorectal cancer being the second leading cause of cancer death and pancreatic cancer carrying one of the worst prognoses of any malignancy. This category of oncology thesis topics addresses the biology, early detection, systemic treatment, and surgical management of gastrointestinal cancers in American patients, with particular attention to the urgent unmet needs in pancreatic and gastric cancer where outcomes remain poor despite recent therapeutic advances.

171. Investigating the FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab comparative effectiveness as first-line therapy for American patients with RAS-mutant metastatic colorectal cancer
172. Analyzing the hepatocellular carcinoma systemic therapy sequencing outcomes — including atezolizumab plus bevacizumab followed by sorafenib versus reverse sequencing — in American patients with advanced disease
173. Developing a pancreatic cancer early detection program using EUS-based surveillance in American adults with new-onset diabetes and weight loss and evaluating its resectability rate at detection
174. Characterizing the KRAS G12D and G12V inhibitor clinical activity and resistance patterns in American patients with KRAS-mutant pancreatic ductal adenocarcinoma in early phase clinical trials
175. Investigating the neoadjuvant FOLFIRINOX chemotherapy effectiveness for increasing resectability rates and improving overall survival in American patients with borderline resectable pancreatic cancer

16. Thoracic and Lung Oncology

Lung cancer remains the leading cause of cancer death in the United States, and the transformation of its treatment through targeted therapies for EGFR, ALK, ROS1, KRAS G12C, and other oncogenic drivers alongside immunotherapy has created a research landscape of extraordinary complexity and productivity. This category of oncology thesis topics addresses lung cancer biology, screening, targeted therapy, immunotherapy, and the management of thoracic malignancies including mesothelioma and thymic tumors in American patients.

176. Investigating the osimertinib adjuvant therapy long-term survival benefits in American patients with resected EGFR-mutant non-small cell lung cancer using extended follow-up from the ADAURA trial
177. Analyzing the amivantamab plus lazertinib combination therapy clinical outcomes and mechanisms of action in American patients with EGFR-mutant non-small cell lung cancer following osimertinib resistance
178. Developing a molecular tumor board consultation program for American oncologists managing patients with rare EGFR exon 20 insertions and other uncommon driver mutations in non-small cell lung cancer
179. Characterizing the KRAS G12C inhibitor combination therapy strategies for overcoming adaptive feedback resistance in American patients with KRAS G12C-mutant non-small cell lung cancer
180. Investigating the consolidation duratiumab immunotherapy effectiveness in American patients with unresectable stage III non-small cell lung cancer following concurrent chemoradiation using real-world outcomes data

17. Breast and Gynecological Oncology

Breast cancer and gynecological malignancies — including ovarian, cervical, uterine, and vulvar cancers — collectively affect hundreds of thousands of American women annually, with ongoing research addressing hereditary cancer syndromes, novel targeted therapies, immunotherapy, and the equity dimensions of gynecological cancer care across diverse American populations.

181. Investigating the olaparib adjuvant therapy efficacy and long-term survival outcomes in American patients with HER2-negative high-risk early breast cancer and germline BRCA mutations
182. Analyzing the sacituzumab govitecan antibody-drug conjugate clinical outcomes across triple-negative and hormone receptor-positive HER2-negative breast cancer subtypes in American real-world oncology settings
183. Developing a BRCA1 and BRCA2 variant of uncertain significance reclassification program for American hereditary breast and ovarian cancer families using functional assay and computational evidence integration
184. Characterizing the endometrial cancer molecular classification impact on adjuvant therapy selection and clinical outcomes in American gynecological oncology practices following TCGA classification adoption
185. Investigating the cervical cancer elimination strategy feasibility in American states with high HPV vaccination coverage using modeling of vaccination, screening, and treatment program integration effectiveness

18. Genitourinary Oncology

Genitourinary cancers — including prostate, kidney, bladder, and testicular cancers — affect hundreds of thousands of American men and women annually, with major therapeutic advances including PARP inhibitors for metastatic prostate cancer, checkpoint inhibitors for renal cell carcinoma, and antibody-drug conjugates for bladder cancer transforming outcomes across this cancer spectrum.

186. Investigating the olaparib plus abiraterone combination therapy outcomes in American patients with metastatic castration-resistant prostate cancer and homologous recombination repair alterations
187. Analyzing the pembrolizumab plus axitinib versus sunitinib long-term outcomes in American patients with advanced clear cell renal cell carcinoma using five-year follow-up data
188. Developing a bladder cancer surveillance protocol optimization for American patients with non-muscle-invasive bladder cancer using enhanced cystoscopy and urine biomarker testing
189. Characterizing the enfortumab vedotin plus pembrolizumab combination therapy outcomes as first-line treatment in American patients with cisplatin-ineligible advanced urothelial carcinoma
190. Investigating the prostate-specific membrane antigen PET/CT staging impact on treatment decisions and outcomes in American patients with biochemically recurrent prostate cancer following radical prostatectomy

19. Neuro-Oncology

Brain and central nervous system tumors represent some of the most devastating and therapeutically challenging cancers, with glioblastoma carrying a median survival of approximately fifteen months despite aggressive multimodal treatment. This category of oncology thesis topics addresses the molecular biology of brain tumors, novel treatment strategies, supportive care, and the neurocognitive dimensions of brain tumor management in American neuro-oncology programs.

191. Investigating the IDH inhibitor vorasidenib effectiveness in American adults with grade two IDH-mutant glioma following surgery using progression-free survival and quality of life outcomes
192. Analyzing the tumor treating fields device adherence patterns and overall survival outcomes in American patients with newly diagnosed glioblastoma receiving standard temozolomide chemoradiation
193. Developing a neurocognitive rehabilitation program for American adults with primary brain tumors experiencing treatment-related cognitive impairment and evaluating its functional outcome effectiveness
194. Characterizing the blood-brain barrier drug delivery strategies — including focused ultrasound-mediated opening — for improving chemotherapy penetration in American glioblastoma patients in early phase clinical trials
195. Investigating the molecular characterization of leptomeningeal metastases using cerebrospinal fluid liquid biopsy in American patients with breast cancer and lung cancer brain metastases

20. Cancer Informatics and Data Science

Cancer informatics and data science address the computational and analytical infrastructure needed to extract insights from the enormous and growing volumes of cancer genomic, imaging, clinical, and patient-reported data generated by American cancer research and care programs.

196. Investigating the natural language processing model performance for automated extraction of cancer staging and treatment information from American tumor registry pathology and clinical notes
197. Analyzing the machine learning model performance for predicting immunotherapy-related adverse event onset from baseline clinical and laboratory features in American oncology electronic health record data
198. Developing a federated learning framework for training cancer recurrence prediction models across American National Cancer Institute-designated cancer center electronic health record networks
199. Characterizing the cancer clinical trial matching algorithm accuracy for identifying eligible American patients from electronic health records compared to manual coordinator-based eligibility screening
200. Investigating the artificial intelligence model performance for predicting pathological complete response to neoadjuvant chemotherapy from baseline breast MRI features in American breast cancer patients

The Range of Oncology Thesis Topics

Current Issues

The immunotherapy revolution has fundamentally transformed American oncology over the past decade — with immune checkpoint inhibitors producing durable responses and functional cures in cancers including metastatic melanoma, non-small cell lung cancer, renal cell carcinoma, and mismatch repair-deficient tumors that were previously considered incurable. Yet the immunotherapy revolution has also created urgent new research questions: why do most patients with most cancers fail to respond to checkpoint inhibitors, what are the optimal combination strategies for overcoming primary and acquired resistance, how can immune-related adverse events be predicted and managed, and how can the extraordinary clinical benefits of immunotherapy be extended to the immunotherapy-resistant majority of American cancer patients. Graduate students developing oncology thesis topics in immunotherapy biology, resistance mechanisms, biomarker development, and toxicity management contribute to the most productive and clinically consequential frontier in contemporary oncology.

Cancer health disparities remain one of the most morally urgent challenges in American oncology, as dramatic survival improvements for Americans with cancer over recent decades have not been distributed equitably — with Black Americans experiencing higher cancer mortality than white Americans for many cancer types despite similar or lower incidence, and with low-income Americans, rural populations, and uninsured Americans facing substantially worse cancer outcomes than their more socioeconomically advantaged counterparts. These disparities reflect not only differential access to early detection and state-of-the-art treatment but also biological differences in tumor molecular characteristics shaped by differential environmental exposures, stress, and treatment history. Graduate students developing oncology thesis topics that rigorously investigate cancer disparities, evaluate disparity-reduction interventions, and contribute to the evidence base for health equity in cancer care address the most socially important research agenda in American oncology.

The precision oncology imperative — matching every cancer patient to the treatment most likely to benefit their specific tumor’s molecular profile — is reshaping clinical trial design, oncology practice, and regulatory science across American cancer care, with comprehensive genomic profiling becoming standard of care for advanced solid tumors and the NCI-MATCH and similar basket trials demonstrating the feasibility of genotype-guided treatment across cancer types. Yet precision oncology also raises important equity concerns, as access to comprehensive genomic profiling, enrollment in biomarker-selected trials, and availability of targeted therapies for rare molecular alterations are not equitably distributed across American cancer patients by race, insurance status, and geographic access to academic cancer centers. Research addressing both the scientific development of precision oncology and its equitable implementation across American oncology settings represents a defining priority for the field.

Recent Trends

Antibody-drug conjugates have emerged as one of the most productive therapeutic platforms in contemporary oncology — combining the tumor-targeting specificity of monoclonal antibodies with the cytotoxic potency of highly active chemotherapy payloads to deliver selective cancer cell killing that is transforming outcomes in breast cancer, urothelial cancer, cervical cancer, and a growing range of other malignancies. Agents including trastuzumab deruxtecan, sacituzumab govitecan, and enfortumab vedotin have each demonstrated clinical activity in settings where previous treatments had failed, and the pipeline of next-generation antibody-drug conjugates targeting novel antigens and incorporating novel payloads is among the most productive in pharmaceutical oncology. Graduate students developing oncology thesis topics in antibody-drug conjugate pharmacology, resistance mechanisms, and clinical optimization are working at one of the most commercially and clinically productive frontiers in cancer therapeutics.

Liquid biopsy — the detection and characterization of circulating tumor DNA, circulating tumor cells, and other tumor-derived materials in blood and other body fluids — is moving rapidly from research tool to clinical application across American oncology, with circulating tumor DNA monitoring enabling earlier detection of cancer recurrence, real-time tracking of treatment response, and identification of resistance mutations before clinical progression is detectable by imaging. Multi-cancer early detection tests based on circulating tumor DNA methylation analysis represent the most transformative potential application — offering the possibility of detecting cancers of multiple types simultaneously from a single blood draw before symptoms develop. Research evaluating the clinical validity, utility, and equity implications of liquid biopsy technologies represents one of the most scientifically exciting and commercially active areas of contemporary oncology research.

Future Directions

Personalized cancer vaccines — individualized mRNA or peptide vaccines encoding the specific neoantigens generated by each patient’s tumor mutations — represent one of the most promising future directions in cancer immunotherapy, with early phase clinical data showing immunogenicity and preliminary efficacy signals in melanoma and lung cancer settings. Future oncology thesis topics will evaluate personalized vaccine clinical effectiveness across cancer types in adjuvant and metastatic settings, investigate the tumor neoantigen landscape characteristics associated with vaccine immunogenicity, develop the manufacturing and computational infrastructure needed to make personalized vaccines clinically and economically viable at American cancer centers, and address the equity challenges of ensuring that highly personalized and potentially expensive vaccine therapies reach all American cancer patients who could benefit.

The convergence of artificial intelligence with oncology has the potential to transform cancer care from pathology and radiology to treatment planning and drug discovery — with AI systems already demonstrating impressive performance on pathological image analysis, radiological tumor characterization, and genomic data interpretation that exceeds or complements human specialist performance. Future oncology thesis topics will develop and validate multimodal AI systems that integrate pathological, radiological, genomic, and clinical data for comprehensive cancer characterization and treatment optimization, evaluate the equity implications of AI-enhanced oncology tools for American cancer patients across different demographic groups and care settings, and investigate the regulatory and governance frameworks needed to ensure that AI in oncology is deployed safely and equitably across the full landscape of American cancer care.

Conclusion

The 200 oncology thesis topics presented across these twenty categories reflect the extraordinary breadth and depth of a discipline that spans molecular cancer biology and cancer epidemiology, precision oncology and immunotherapy, radiation oncology and surgical oncology, palliative care and survivorship, cancer health disparities and health services research, and the emerging frontiers of personalized cancer vaccines and AI-assisted oncology. Students pursuing oncology thesis topics at American universities engage with research questions of profound scientific complexity and immediate human consequence — questions whose answers will determine whether the pace of therapeutic progress in oncology continues to accelerate, whether its benefits reach all Americans equitably, and whether the next generation of cancer patients in the United States experiences a world where cancer is increasingly a chronic manageable condition or even a curable disease. Career pathways extend into academic oncology research, pharmaceutical drug development, cancer epidemiology, cancer health policy, global oncology, and the technology companies developing the next generation of cancer diagnostics and therapeutics — all domains where rigorously trained oncology scholars make lasting contributions to reducing the burden of cancer in America and beyond.

Academic Support

iResearchNet provides expert academic support for graduate students developing oncology thesis topics across the full spectrum of this discipline’s scientific, clinical, epidemiological, and health policy dimensions. Our consultants bring specialized expertise in cancer biology, cancer epidemiology, cancer screening, medical oncology, radiation oncology, surgical oncology, palliative care, cancer survivorship, cancer health disparities, precision oncology, immunotherapy, hematological malignancies, pediatric oncology, and cancer informatics — with direct experience supporting students in American oncology fellowship research programs, cancer epidemiology doctoral training, clinical research fellowships, and health services research programs focused on cancer care quality and equity. Whether you are designing a cancer clinical trial, analyzing population-based cancer registry data, developing an immunotherapy biomarker study, building a cancer health disparities research program, or evaluating a novel cancer care delivery intervention, iResearchNet’s support is oriented toward strengthening your scholarly development and deepening your engagement with oncology as a research discipline. Our mission is to support your intellectual growth, not to substitute for the original thinking that defines excellent graduate scholarship in oncology.